A Phase 3 interventional study of Gabapentin and Diphenhydramine citrate in Healthy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 4 sites in United States. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders — none open to participants now, none under way, none of them phase 3. Gabapentin · Sleep Initiation and Maintenance Disorders.
Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, this one is the 9th largest by enrollment, is the only one that started in 2013, is one of 9 in phase 3, and was the 13th registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →None of the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →
Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →
Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.
This study: 25 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 68 across 2,356 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 283 across the 14 interventional studies. Of the 14 that completed or were terminated, 2 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 6 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 9 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine the next-day residual effects of a nighttime dose of gabapentin 250 mg, diphenhydramine citrate 76 mg and triazolam 0.5 mg compared to placebo and each other on simulated driving performance in normal volunteer subjects. It will also examine other measures of next-day performance and next-day sleepiness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Gabapentin
Drug: Diphenhydramine citrate
Drug: Triazolam
Drug: Placebo
250 mg, oral, prior to bedtime on the night before performance testing
76 mg, oral, prior to bedtime on the night before performance testing
0.5 mg, oral, prior to bedtime on the night before performance testing
Oral, prior to bedtime on the night before performance testing
Standard Deviation of Lateral Position (SDLP)
Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). SDLP was used to assess driver's ability to track their lane and was the standard deviation of lane positions through the entire drive.
Time frame: 7.25 hours post-dose
Speed Deviation
Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Standard deviation of speed was reported in the outcome measure.
Time frame: 7.25 hours post dose
Lane Exceedance
Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Mean lanes excursed/exceeded was reported in the outcome measure.
Time frame: 7.25 hours post-dose
| Milestone | Diphenhydramine Citrate, Gabapentin, Placebo, Triazolam | Gabapentin, Triazolam, Diphenhydramine Citrate, Placebo | Triazolam, Placebo, Gabapentin, Diphenhydramine Citrate | Placebo, Diphenhydramine Citrate, Triazolam, Gabapentin |
|---|---|---|---|---|
| Started | 13 | 14 | 15 | 17 |
| Completed | 13 | 14 | 15 | 17 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Diphenhydramine Citrate, Gabapentin, Placebo, Triazolam | Gabapentin, Triazolam, Diphenhydramine Citrate, Placebo | Triazolam, Placebo, Gabapentin, Diphenhydramine Citrate | Placebo, Diphenhydramine Citrate, Triazolam, Gabapentin |
|---|---|---|---|---|
| Started | 13 | 14 | 15 | 17 |
| Completed | 13 | 14 | 14 | 16 |
| Not completed | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 |
| Milestone | Diphenhydramine Citrate, Gabapentin, Placebo, Triazolam | Gabapentin, Triazolam, Diphenhydramine Citrate, Placebo | Triazolam, Placebo, Gabapentin, Diphenhydramine Citrate | Placebo, Diphenhydramine Citrate, Triazolam, Gabapentin |
|---|---|---|---|---|
| Started | 13 | 14 | 14 | 16 |
| Completed | 13 | 14 | 14 | 16 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Diphenhydramine Citrate, Gabapentin, Placebo, Triazolam | Gabapentin, Triazolam, Diphenhydramine Citrate, Placebo | Triazolam, Placebo, Gabapentin, Diphenhydramine Citrate | Placebo, Diphenhydramine Citrate, Triazolam, Gabapentin |
|---|---|---|---|---|
| Started | 13 | 14 | 14 | 16 |
| Completed | 13 | 14 | 14 | 14 |
| Not completed | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Milestone | Diphenhydramine Citrate, Gabapentin, Placebo, Triazolam | Gabapentin, Triazolam, Diphenhydramine Citrate, Placebo | Triazolam, Placebo, Gabapentin, Diphenhydramine Citrate | Placebo, Diphenhydramine Citrate, Triazolam, Gabapentin |
|---|---|---|---|---|
| Started | 13 | 14 | 14 | 14 |
| Completed | 13 | 14 | 14 | 14 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Diphenhydramine Citrate, Gabapentin, Placebo, Triazolam | Gabapentin, Triazolam, Diphenhydramine Citrate, Placebo | Triazolam, Placebo, Gabapentin, Diphenhydramine Citrate | Placebo, Diphenhydramine Citrate, Triazolam, Gabapentin |
|---|---|---|---|---|
| Started | 13 | 14 | 14 | 14 |
| Completed | 13 | 14 | 14 | 14 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Diphenhydramine Citrate, Gabapentin, Placebo, Triazolam | Gabapentin, Triazolam, Diphenhydramine Citrate, Placebo | Triazolam, Placebo, Gabapentin, Diphenhydramine Citrate | Placebo, Diphenhydramine Citrate, Triazolam, Gabapentin |
|---|---|---|---|---|
| Started | 13 | 14 | 14 | 14 |
| Completed | 13 | 14 | 14 | 14 |
| Not completed | 0 | 0 | 0 | 0 |
Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). SDLP was used to assess driver's ability to track their lane and was the standard deviation of lane positions through the entire drive.
| centimeter (cm) | Placebo | Gabapentin | Diphenhydramine Citrate | Triazolam |
|---|---|---|---|---|
| Standard Deviation of Lateral Position (SDLP) | 33.2 ± 8.0 | 34.2 ± 10.0 | 35.4 ± 8.9 | 47.4 ± 12.0 |
Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Standard deviation of speed was reported in the outcome measure.
| meters per second (m/sec) | Placebo | Gabapentin | Diphenhydramine Citrate | Triazolam |
|---|---|---|---|---|
| Speed Deviation | 0.9 ± 0.3 | 0.9 ± 0.3 | 1.0 ± 0.3 | 1.3 ± 0.6 |
Driving performance assessment for the participants were measured by simulated driving test using Cognitive Research Corporation Driving Simulator (CRCDS-MiniSim). The assessment was performed after 45 minutes of awakening from approximately 6.5 hours of sleep on testing day (after 7.25 hours of study drug administration). Mean lanes excursed/exceeded was reported in the outcome measure.
| lanes exceeded | Placebo | Gabapentin | Diphenhydramine Citrate | Triazolam |
|---|---|---|---|---|
| Lane Exceedance | 37.8 ± 45.9 | 46.7 ± 58.5 | 52.4 ± 62.0 | 147.7 ± 113.6 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/58 (0%) | 3/58 (5.2%) |
| Gabapentin | — | 0/55 (0%) | 2/55 (3.6%) |
| Diphenhydramine Citrate | — | 0/57 (0%) | 3/57 (5.3%) |
| Triazolam | — | 0/56 (0%) | 10/56 (17.9%) |
| Event | Placebo | Gabapentin | Diphenhydramine Citrate | Triazolam |
|---|---|---|---|---|
| SomnolenceNervous system disorders | 0/58 | 0/55 | 1/57 | 6/56 |
| LethargyNervous system disorders | 0/58 | 0/55 | 0/57 | 3/56 |
| NauseaGastrointestinal disorders | 0/58 | 2/55 | 1/57 | 2/56 |
| Sensation of foreign bodyGeneral disorders | 0/58 | 0/55 | 0/57 | 1/56 |
| DizzinessNervous system disorders | 0/58 | 0/55 | 0/57 | 1/56 |
| HeadacheNervous system disorders | 0/58 | 0/55 | 1/57 | 1/56 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/58 | 0/55 | 1/57 | 0/56 |
| Vision blurredEye disorders | 1/58 | 0/55 | 0/57 | 0/56 |
| Abdominal pain upperGastrointestinal disorders | 1/58 | 0/55 | 0/57 | 0/56 |
| Dry mouthGastrointestinal disorders | 1/58 | 0/55 | 0/57 | 0/56 |
Intent to Treat (ITT) population included all randomized participants who received at least 1 dose of investigational product and provided any data post-randomization.
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 41.1 ± 9.0 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 13 |
| Male | 46 |
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2013 to primary completion in Dec 2013, 4 months.
Results were first posted in Feb 2021, 7 years 1 month after primary completion. A results delay was requested in Dec 2014.
Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 4 months is below that.
Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gabapentin · Diphenhydramine
Sleep Initiation and Maintenance Disorders →
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →